School of Chemical Sciences, Swami Ramanand Teerth Marathwada University, Nanded, MS, 431606, India.
School of Life Sciences, Swami Ramanand Teerth Marathwada University, Nanded, MS, 431606, India.
Comput Biol Chem. 2019 Jun;80:54-65. doi: 10.1016/j.compbiolchem.2019.03.002. Epub 2019 Mar 13.
Development of novel, safe and effective drug candidates combating the emerging drug resistance has remained a major focus in the mainstream of anti-tuberculosis research. Here, we inspired to design and synthesize series of new pyridin-4-yl-1,3,4-oxadiazol-2-yl-thio-ethylidene-hydrazinecarbothioamide derivatives as potential anti-tubercular agents. The anti-tubercular bioactive assay demonstrated that the synthesized compounds exhibit potent anti-tubercular activity (MIC = 3.9-7.81 μg/mL) in comparison with reference drugs Rifampicin and Isoniazid.We employed pharmacophore probing approach for the identification of CYP51 as a possible drug target for the synthesized compounds. To understand the preferable binding mode, the synthesized molecules were docked onto the active site of Sterol 14 α-demethylases (CYP51) target. From the binding free energy of the docking results it was revealed that the compounds were effective CYP51 inhibitors and acts as antitubercular agent.
开发新型、安全且有效的药物候选物以对抗新兴的耐药性一直是主流抗结核研究的重点。在这里,我们受到启发,设计并合成了一系列新型的吡啶-4-基-1,3,4-噁二唑-2-基-硫代-乙叉-腙甲硫酰胺衍生物,作为潜在的抗结核药物。抗结核生物活性测定表明,与对照药物利福平 (Rifampicin) 和异烟肼 (Isoniazid) 相比,合成的化合物具有很强的抗结核活性 (MIC = 3.9-7.81μg/mL)。我们采用药效团探测方法确定 CYP51 作为合成化合物的可能药物靶点。为了了解优选的结合模式,将合成的分子对接至甾醇 14α-脱甲基酶 (CYP51) 靶标上的活性位点。从对接结果的结合自由能来看,这些化合物是有效的 CYP51 抑制剂,并且具有抗结核作用。